Gain detailed insights into the trading activity of Congress members for Pacira BioSciences on our government trades page. Stay updated on how elected officials are investing in PCRX.

Pacira BioSciences - Government Trades

Pacira BioSciences

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.

movers image

News

Intraday Update

Markets

Movers

Trading Ideas

MRUS

MVST

PCRX

RPRX

TALO

TD Synnex, Walgreens, Savers Value Village And Other Big Stocks Moving Higher On Friday

Health Care

General

Pacira launches a new iovera° Smart Tip for chronic back pain relief, offering an alternative to radiofrequency ablation with promising study results.

Pacira BioSciences Secures FDA Approval For New iovera SmartTip to Manage Chronic Low Back Pain

Analyst Color

Biotech

Equities

Downgrades

Price Target

Legal

Analyst Ratings

Pacira BioSciences faces a significant setback as the U.S. District Court invalidates its key patent on Exparel, leading to a 40% stock drop. Exparel, crucial to Pacira&#39;s revenue, is now vulnerable, prompting a downgrade from JP Morgan with a new price target of $10.

Pain Management-Focused Pacira BioSciences Loses Patent Fight For Key Drug, JP Morgan Analyst Downgrades On Unclear Path

JetBlue

Pre-Market Outlook

AILE

FTRE

JBLU

MARA

RILY

JetBlue Airways, B. Riley Financial, Hawaiian Electric And Other Big Stocks Moving Lower In Monday&#39;s Pre-Market Session

Healthcare

Long Ideas

CSTL

SAVA

Top 5 Health Care Stocks That May Explode In July

Image27

AZEK

CHTR

This Charter Communications Analyst Turns Bearish; Here Are Top 5 Downgrades For Wednesday

Earnings

Guidance

Small Cap

Pacira BioSciences Inc (NASDAQ: PCRX) reported Q1 sales of $160.3 million compared to $158.0 million a year ago and the 

Why Pacira BioSciences Shares Are Trading Lower Today

Penny Stocks

AVTE

KYMR

MMAT

NKLA

SatixFy Communications Ltd. Ordinary Share

SATX

SWIM

VNDA

U.S. stocks traded slightly higher, with the Nasdaq Composite gaining around 70 points on Tuesday. Here are some big stocks recording losses in today’s session.

JetBlue Airways, Pacira BioSciences And Some Other Big Stocks Moving Lower On Tuesday

Pacira Touts Positive Data From EXPAREL Study In Toe Correction Surgery

Benzinga Pharma News

BCYC

DBVT

ERAS

GKOS

IONS

MCRB

NBTX

SILK

VIRX

VRAY

Important Biotech Catalysts For September 7, 2022 - End Of The Day Summary

Pacira BioSciences Inc

Truist Securities analyst Les Sulewski upgrades Pacira BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) from Sell to Hold and raises the price target from $8 to $25.

Upgrades

Truist Securities Upgrades Pacira BioSciences to Hold, Raises Price Target to $25

-- Accomplished Business and Financial Leader, Laura Brege, Appointed Chair --
-- Paul J. Hastings and Andreas Wicki, PhD Retire from Board of Directors --
PARSIPPANY, N.J., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that Laura Brege has been appointed Chair of the Board. Former Chair Paul J. Hastings and Andreas Wicki, PhD. have retired from the Board. These changes align with Pacira's ongoing commitment to Board refreshment. With these changes, the Board is composed of nine directors, eight of whom are independent and five of whom have joined since October 2023. Each director brings expertise in areas important to Pacira's business to support Pacira's 5x30 growth-oriented plan including executive leadership, M&amp;A, research and development, operations, commercialization, manufacturing and supply chain.

Management

Pacira Announces That Laura Brege Has Been Appointed Chair Of The Board

RBC Capital analyst Gregory Renza reiterates Pacira BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) with a Sector Perform and maintains $18 price target.

Reiteration

RBC Capital Reiterates Sector Perform on Pacira BioSciences, Maintains $18 Price Target

In the last three months, 6 analysts have published ratings on Pacira BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>), offering a diverse range of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $25.67, a high estimate of $39.00, and a low estimate of $16.00. Marking an increase of 6.21%, the current average surpasses the previous average price target of $24.17. 
<img src="https://www.benzinga.com/files/images/story/2025/1736776826_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A clear picture of Pacira BioSciences's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$30.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$30.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Oren Livnat</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$39.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Balaji Prasad</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$17.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$16.00</td>
<td>$15.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Pacira BioSciences. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Pacira BioSciences compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Pacira BioSciences's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Pacira BioSciences's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/PCRX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Pacira BioSciences analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Get to Know Pacira BioSciences Better</h2>
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.
<h3>Unraveling the Financial Story of Pacira BioSciences</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Over the 3 months period, Pacira BioSciences showcased positive performance, achieving a revenue growth rate of 2.83% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -85.11%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Pacira BioSciences's ROE excels beyond industry benchmarks, reaching -17.62%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Pacira BioSciences's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -9.06%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Pacira BioSciences's debt-to-equity ratio is below the industry average. With a ratio of 0.86, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Significance of Analyst Ratings Explained</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

6 Analysts Assess Pacira BioSciences: What You Need To Know

Needham analyst Serge Belanger maintains Pacira BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) with a Buy and raises the price target from $22 to $30.

Needham Maintains Buy on Pacira BioSciences, Raises Price Target to $30

U.S. stocks were lower, with the Dow Jones index falling over 700 points on Friday.
Shares of TD Synnex Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNX#NYSE">SNX</a>) rose sharply in today's session after the company reported <a href="https://www.benzinga.com/25/01/42915528/td-synnex-shares-delivers-earnings-beat-and-boosts-dividend-by-10">better-than-expected quarterly financial results.</a>
Quarterly revenue of $15.85 billion, up 10% Y/Y, exceeded the analyst view of $15.22 billion. The Fremont, California-based company reported an adjusted EPS of $3.09, beating the street view of $3.05.
TD Synnex shares jumped 5.5% to $128.76 on Friday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Microvast Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVST#NASDAQ">MVST</a>) shares jumped 37.3% to $2.57 after the company announced a developments in its True All-Solid-State Battery technology.</li>
<li>Walgreens Boots Alliance Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) gained 23.6% to $11.40 after the company reported better-than-expected first-quarter financial results.</li>
<li>Savers Value Village Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SVV#NYSE">SVV</a>) surged 13.5% to $10.63 after the company reported preliminary fourth quarter and full year net sales.</li>
<li>Oculis Holding AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCS#NASDAQ">OCS</a>) gained 13.1% to $21.14.</li>
<li>Sasol Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SSL#NYSE">SSL</a>) gained 13.1% to $4.99.</li>
<li>Pacira Biosciences Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) climbed 12.1% to $20.83 after the company reported a preliminary year-over-year increase in FY25 revenue.</li>
<li>Royalty Pharma plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>) gained 10.6% to $28.97 after the company announced it increased its quarterly dividend.</li>
<li>Merus NV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) gained 9.8% to $46.35.</li>
<li>Teekay Tankers Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TNK#NYSE">TNK</a>) rose 8.1% to $45.56.</li>
<li>Talos Energy Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TALO#NYSE">TALO</a>) gained 6.2% to $10.58.</li>
<li>TD Synnex Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNX#NYSE">SNX</a>) rose 5.5% to $128.76 after the company reported better-than-expected quarterly financial results.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42912948/top-3-materials-stocks-that-are-set-to-fly-this-month">Top 3 Materials Stocks That Are Set To Fly This Month</a></li>
</ul>

WIIM

Pacira Biosciences shares are trading higher after the company reported a preliminary year-over-year increase in FY25 revenue.

5x30 Path to growth and value creation
The company intends to achieve the following five objectives by 2030 ("5x30"):
<ul>
<li>Patients: More than three million patients treated per year</li>
<li>Product revenue: Double-digit compounded annual growth rate</li>
<li>Profitability: Five percentage point gross margin improvement over 2024</li>
<li>Pipeline: Clinical pipeline expansion with five novel programs in development</li>
<li>Partnerships: Establishing five partnerships including pipeline and commercial agreements</li>
</ul>

Pacira Reports Prelim. 2024 Revenue Of $710M vs $675.0M YoY; Co. Sets 2030 Goals Including More Than 3M Patients Treated Yearly

On Tuesday, Pacira BioSciences, Inc.&nbsp; (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) received FDA clearance to market a new Smart Tip designed to access the medial branch nerves to manage chronic <a target="_blank" href="https://www.benzinga.com//node/42841844" rel="noreferrer noopener">low back pain</a>.
The ioveraº system is a drug-free treatment that relieves pain via cryoneurolysis—a process whereby focused cold therapy is applied to a targeted nerve, temporarily interrupting its ability to transmit pain signals.
Pain relief is typically experienced immediately after treatment, lasting for months as the nerve regenerates.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40321378/pain-management-focused-pacira-biosciences-loses-patent-fight-for-key-drug-jp-morga" rel="noreferrer noopener">Pain Management-Focused Pacira BioSciences Loses Patent Fight For Key Drug, JP Morgan Analyst Downgrades On Unclear Path</a>
To date, the ioveraº portfolio has consisted of either a three-pronged Smart Tip featuring 8.5-mm long 27-gauge needles to treat superficial nerves or a single, 90-mm long, 20-guage Smart Tip ideally suited to treat deeper nerves.
It is most commonly used to treat knee pain but frequently used to manage pain in the hip, shoulder, chest, foot &amp; ankle, and more.
This new, 25-gauge 180-mm Smart Tip will allow for the treatment of deeper nerves, such as the medial branch nerve. It is specifically designed to relieve chronic low back pain associated with facet-mediated pain.
This longer-needle Smart Tip is designed for use through a cannula or introducer, allowing ice ball formation at deeper peripheral nerves.
Annually, 28 to 30 million Americans seek treatment for chronic back pain, yet only 2 to 3 million undergo interventional procedures.
With the introduction of this new iovera° Smart Tip, Pacira aims to address these gaps and elevate the standard of care.
The company adds that the product offers an alternative to conventional treatments, such as radiofrequency ablation, with substantial limitations.
A single-center randomized pilot study of the iovera° system showed:
<ul>
<li>Patients treated with iovera° reported pain scores more than 2 points lower at 180 and 360 days than those treated with RFA on the 0-10 NRS Pain scale.</li>
<li>At 360 days, patients in the iovera° group showed statistically and clinically significant improvements in functional outcomes, as evidenced by average Oswestry Disability Index (ODI) scores improving from moderate to minimal disability.</li>
<li>More iovera° patients expressed satisfaction with their pain management compared to those receiving RFA.</li>
<li>No serious adverse events were observed over the course of the study.</li>
</ul>
Price Action: PCRX stock is up 1.50% at $18.91 at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42846580/rpm-international-q2-strong-sales-adjusted-ebit-growth-and-updated-fy25-guidance" target="_blank" rel="noreferrer noopener">Paint &amp; Coating Company RPM Beats Q2 Expectations But Signals Flat Q3; Stock Dips</a></li>
</ul>

Pacira Biosciences shares are trading higher after the company announced it received FDA 510k clearance to market its new iovera° SmartTIp for chronic lower back pain via a medial branch nerve block.

Pacira BioSciences Receives FDA 510k Clearance To Market New iovera° SmartTip For Chronic Low Back Pain via Medial Branch Nerve Block

Across the recent three months, 6 analysts have shared their insights on Pacira BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $21.17, a high estimate of $39.00, and a low estimate of $15.00. Highlighting a 2.31% decrease, the current average has fallen from the previous average price target of $21.67. 
<img src="https://www.benzinga.com/files/images/story/2024/1733313644_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of Pacira BioSciences among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oren Livnat</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$39.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Balaji Prasad</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$17.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$22.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$16.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$15.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Glen Santangelo</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$18.00</td>
<td>$15.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Pacira BioSciences. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Pacira BioSciences compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Pacira BioSciences's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Pacira BioSciences's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/PCRX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Pacira BioSciences analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>About Pacira BioSciences</h2>
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.
<h3>Key Indicators: Pacira BioSciences's Financial Health</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Pacira BioSciences showcased positive performance, achieving a revenue growth rate of 2.83% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Pacira BioSciences's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -85.11%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Pacira BioSciences's ROE excels beyond industry benchmarks, reaching -17.62%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Pacira BioSciences's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -9.06%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Pacira BioSciences's debt-to-equity ratio is below the industry average. With a ratio of 0.86, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Decoding 6 Analyst Evaluations For Pacira BioSciences

HC Wainwright &amp; Co. analyst Oren Livnat reiterates Pacira BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) with a Buy and maintains $39 price target.

HC Wainwright & Co. Reiterates Buy on Pacira BioSciences, Maintains $39 Price Target

Pacira Biosciences Received U.S. Patent No. 12,156,940 From The U.S. Patent And Trademark Office, Which Protects The Chemical Composition Of Exparel (Bupivacaine Liposome Injectable Suspension). The Company Expects The '940 Patent To Provide Protection Into July 2044

Pacira Secures New U.S. Patent For EXPAREL Composition, Expanding IP Protection Through 2044

Pacira Reports 104-Week Safety And Efficacy Data Following Local Administration Of PCRX-201 For Moderate To Severe Osteoarthritis Of Knee

Barclays analyst Balaji Prasad maintains Pacira BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) with a Equal-Weight and lowers the price target from $25 to $17.

Barclays Maintains Equal-Weight on Pacira BioSciences, Lowers Price Target to $17

Needham analyst Serge Belanger reiterates Pacira BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) with a Buy and maintains $22 price target.

Needham Reiterates Buy on Pacira BioSciences, Maintains $22 Price Target

Providing a diverse range of perspectives from bullish to bearish, 8 analysts have published ratings on Pacira BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) in the last three months.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $17.75, a high estimate of $39.00, and a low estimate of $8.00. This current average has decreased by 44.53% from the previous average price target of $32.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1731009644_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The perception of Pacira BioSciences by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$16.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$15.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Glen Santangelo</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$18.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Les Sulewski</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Sell</td>
<td>$8.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$14.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Oren Livnat</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$39.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$22.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Hardik Parikh</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$10.00</td>
<td>$45.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Pacira BioSciences. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Pacira BioSciences compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Pacira BioSciences's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Pacira BioSciences's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PCRX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Pacira BioSciences analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Discovering Pacira BioSciences: A Closer Look</h2>
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.
<h3>Pacira BioSciences: Financial Performance Dissected</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Positive Revenue Trend: Examining Pacira BioSciences's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 5.05% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Pacira BioSciences's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 10.61% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 2.13%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Pacira BioSciences's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.17% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Pacira BioSciences's debt-to-equity ratio is below the industry average at 0.74, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Evaluating Pacira BioSciences: Insights From 8 Financial Analysts

RBC Capital analyst Gregory Renza maintains Pacira BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) with a Sector Perform and raises the price target from $15 to $16.

RBC Capital Maintains Sector Perform on Pacira BioSciences, Raises Price Target to $16

Press Releases

ROSEN, A LEADING LAW FIRM, Encourages Pacira BioSciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PCRX

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 14, 2025 in Pacira BioSciences, Inc. Lawsuit - PCRX

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Pacira Biosciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - PCRX

PACIRA BIOSCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Pacira BioSciences, Inc. - PCRX

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira

Investors in Pacira BioSciences, Inc. Should Contact The Gross Law Firm Before March 14, 2025 to Discuss Your Rights – PCRX

PACIRA BIOSCIENCES SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Pacira BioSciences, Inc. - PCRX

The Gross Law Firm Notifies Shareholders of Pacira BioSciences, Inc. (PCRX) of a Class Action Lawsuit and an Upcoming Deadline

Pacira Announces Updates to Board of Directors

PCRX LAWSUIT ALERT: Levi & Korsinsky Notifies Pacira BioSciences, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

Government Trades

Pacira BioSciences Inc

top performing PCRX trades

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga